Public-registry site landscape for NCT07707895, “DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers”, a Small Cell Lung Cancer study sponsored by Boehringer Ingelheim. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07707895 (registry record) |
| Study title | DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers |
| Official title | A Phase Ib/II, Open-label, Safety and Tolerability Trial of Obrixtamig in Combination With ZL-1310 in Patients With Poorly Differentiated NEC |
| Sponsor | Boehringer Ingelheim |
| Condition(s) | Small Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma; Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology; Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 24 |
| Site countries | United States, Australia, Belgium, China, France, Germany, Japan, Netherlands, Poland, Spain, United Kingdom |
At MedStar Georgetown University Hospital — one of the facilities listed on this trial — 9 other studies are actively recruiting Small Cell Lung Cancer patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07707895.
Eichor generates a preliminary site-risk snapshot for NCT07707895 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
